Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apomorphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.95 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.95 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.95 |
| ▸ | HPGD | P15428 | 6/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.95 |
| ▸ | MAPT | P10636 | 5/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.95 |
| ▸ | TP53 | P04637 | 4/20 | 0.95 |
| ▸ | PKM | P14618 | 4/20 | 0.95 |
| ▸ | LMNA | P02545 | 4/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.95 |
| ▸ | GAA | P10253 | 3/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.95 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.95 |
| ▸ | HTR1A | P08908 | 3/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apomorphine SCHEMBL8525 | 0.99 | KDM4E (0.93) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL29599870 | 0.97 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL5605456 | 0.97 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL29414090 | 0.97 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL8541 | 0.97 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| (S)Apomorphine SCHEMBL6922802 | 0.97 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| (S)Apomorphine SCHEMBL30554804 | 0.97 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL1923763 | 0.97 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL29358024 | 0.97 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| Apomorphine SCHEMBL17870682 | 0.96 | KDM4E (0.98) | KDM4EALDH1A1HPGDHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190015423-A1 | REGULATION OF GENE EXPRESSION BY MODULATING PRIMARY CILIA LENGTH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-17 | — | — | US | claimed |
| WO-2017173103-A1 | REGULATION OF GENE EXPRESSION BY MODULATING PRIMARY CILIA LENGTH | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-10-05 | — | — | WO | claimed |
| US-12109221-B2 | Combination therapy for treating cancer | LEUKOS BIOTECH, S.L. (ES) | 2024-10-08 | — | — | US | disclosed |
| US-20230122940-A1 | COMBINATION THERAPY FOR TREATING CANCER | LEUKOS BIOTECH, S.L. (ES) | 2023-04-20 | — | — | US | disclosed |
| US-20220323456-A1 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS (ES) | 2022-10-13 | — | — | US | disclosed |
| US-11446321-B2 | Combination therapy for treating cancer | LEUKOS BIOTECH, S.L. (ES) | 2022-09-20 | — | — | US | disclosed |
| US-11337984-B2 | Methods for treating, diagnosing and prognosing a haematological malignancy | INSTITUT DE RECERCA CONTRA LA LEUCÉMIA JOSEP CARRERAS (ES) | 2022-05-24 | — | — | US | disclosed |
| US-20210228593-A1 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS (ES) | 2021-07-29 | — | — | US | disclosed |
| EP-3160472-B1 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | INST DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS (ES) | 2020-03-11 | — | — | EP | disclosed |
| US-20190343843-A1 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS (ES) | 2019-11-14 | — | — | US | disclosed |
| CN-106471373-B | For treating, diagnosing and the method for prognosis Malignancy | 约瑟卡雷拉斯白血球过多症研究所 | 2019-08-23 | — | — | CN | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | DRD2 1115/4885DRD4 1556/4885DRD3 1620/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | DRD2 4305/4885DRD4 4415/4885DRD3 4363/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | DRD2 2243/4885DRD4 2205/4885DRD3 2501/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | DRD2 647/4885DRD4 737/4885DRD3 922/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | DRD2 1528/4885DRD4 1926/4885DRD3 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.